Copyright Reports & Markets. All rights reserved.

Global Gene Cell Therapy CDMO Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Gene Cell Therapy CDMO by Type
    • 1.3.1 Overview: Global Gene Cell Therapy CDMO Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Gene Cell Therapy CDMO Consumption Value Market Share by Type in 2025
    • 1.3.3 Immune Cells
    • 1.3.4 Stem Cell
    • 1.3.5 Viral Vector
    • 1.3.6 Plasmid DNA
  • 1.4 Global Gene Cell Therapy CDMO Market by Application
    • 1.4.1 Overview: Global Gene Cell Therapy CDMO Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Pharmaceutical and Biotechnology Companies
    • 1.4.3 Research and Academic Institutions
    • 1.4.4 Hospital
    • 1.4.5 Others
  • 1.5 Global Gene Cell Therapy CDMO Market Size & Forecast
  • 1.6 Global Gene Cell Therapy CDMO Market Size and Forecast by Region
    • 1.6.1 Global Gene Cell Therapy CDMO Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Gene Cell Therapy CDMO Market Size by Region, (2021-2032)
    • 1.6.3 North America Gene Cell Therapy CDMO Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Gene Cell Therapy CDMO Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Gene Cell Therapy CDMO Market Size and Prospect (2021-2032)
    • 1.6.6 South America Gene Cell Therapy CDMO Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Gene Cell Therapy CDMO Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Catalent
    • 2.1.1 Catalent Details
    • 2.1.2 Catalent Major Business
    • 2.1.3 Catalent Gene Cell Therapy CDMO Product and Solutions
    • 2.1.4 Catalent Gene Cell Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Catalent Recent Developments and Future Plans
  • 2.2 Lonza
    • 2.2.1 Lonza Details
    • 2.2.2 Lonza Major Business
    • 2.2.3 Lonza Gene Cell Therapy CDMO Product and Solutions
    • 2.2.4 Lonza Gene Cell Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Lonza Recent Developments and Future Plans
  • 2.3 Thermo Fisher
    • 2.3.1 Thermo Fisher Details
    • 2.3.2 Thermo Fisher Major Business
    • 2.3.3 Thermo Fisher Gene Cell Therapy CDMO Product and Solutions
    • 2.3.4 Thermo Fisher Gene Cell Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Thermo Fisher Recent Developments and Future Plans
  • 2.4 ACG Biologics
    • 2.4.1 ACG Biologics Details
    • 2.4.2 ACG Biologics Major Business
    • 2.4.3 ACG Biologics Gene Cell Therapy CDMO Product and Solutions
    • 2.4.4 ACG Biologics Gene Cell Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 ACG Biologics Recent Developments and Future Plans
  • 2.5 Charles River
    • 2.5.1 Charles River Details
    • 2.5.2 Charles River Major Business
    • 2.5.3 Charles River Gene Cell Therapy CDMO Product and Solutions
    • 2.5.4 Charles River Gene Cell Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Charles River Recent Developments and Future Plans
  • 2.6 Oxford Biomedica
    • 2.6.1 Oxford Biomedica Details
    • 2.6.2 Oxford Biomedica Major Business
    • 2.6.3 Oxford Biomedica Gene Cell Therapy CDMO Product and Solutions
    • 2.6.4 Oxford Biomedica Gene Cell Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Oxford Biomedica Recent Developments and Future Plans
  • 2.7 Novartis
    • 2.7.1 Novartis Details
    • 2.7.2 Novartis Major Business
    • 2.7.3 Novartis Gene Cell Therapy CDMO Product and Solutions
    • 2.7.4 Novartis Gene Cell Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Novartis Recent Developments and Future Plans
  • 2.8 OBiO
    • 2.8.1 OBiO Details
    • 2.8.2 OBiO Major Business
    • 2.8.3 OBiO Gene Cell Therapy CDMO Product and Solutions
    • 2.8.4 OBiO Gene Cell Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 OBiO Recent Developments and Future Plans
  • 2.9 GenScript
    • 2.9.1 GenScript Details
    • 2.9.2 GenScript Major Business
    • 2.9.3 GenScript Gene Cell Therapy CDMO Product and Solutions
    • 2.9.4 GenScript Gene Cell Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 GenScript Recent Developments and Future Plans
  • 2.10 Pharmaron
    • 2.10.1 Pharmaron Details
    • 2.10.2 Pharmaron Major Business
    • 2.10.3 Pharmaron Gene Cell Therapy CDMO Product and Solutions
    • 2.10.4 Pharmaron Gene Cell Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Pharmaron Recent Developments and Future Plans
  • 2.11 Porton
    • 2.11.1 Porton Details
    • 2.11.2 Porton Major Business
    • 2.11.3 Porton Gene Cell Therapy CDMO Product and Solutions
    • 2.11.4 Porton Gene Cell Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Porton Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Gene Cell Therapy CDMO Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Gene Cell Therapy CDMO by Company Revenue
    • 3.2.2 Top 3 Gene Cell Therapy CDMO Players Market Share in 2025
    • 3.2.3 Top 6 Gene Cell Therapy CDMO Players Market Share in 2025
  • 3.3 Gene Cell Therapy CDMO Market: Overall Company Footprint Analysis
    • 3.3.1 Gene Cell Therapy CDMO Market: Region Footprint
    • 3.3.2 Gene Cell Therapy CDMO Market: Company Product Type Footprint
    • 3.3.3 Gene Cell Therapy CDMO Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Gene Cell Therapy CDMO Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Gene Cell Therapy CDMO Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Gene Cell Therapy CDMO Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Gene Cell Therapy CDMO Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Gene Cell Therapy CDMO Consumption Value by Type (2021-2032)
  • 6.2 North America Gene Cell Therapy CDMO Market Size by Application (2021-2032)
  • 6.3 North America Gene Cell Therapy CDMO Market Size by Country
    • 6.3.1 North America Gene Cell Therapy CDMO Consumption Value by Country (2021-2032)
    • 6.3.2 United States Gene Cell Therapy CDMO Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Gene Cell Therapy CDMO Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Gene Cell Therapy CDMO Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Gene Cell Therapy CDMO Consumption Value by Type (2021-2032)
  • 7.2 Europe Gene Cell Therapy CDMO Consumption Value by Application (2021-2032)
  • 7.3 Europe Gene Cell Therapy CDMO Market Size by Country
    • 7.3.1 Europe Gene Cell Therapy CDMO Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Gene Cell Therapy CDMO Market Size and Forecast (2021-2032)
    • 7.3.3 France Gene Cell Therapy CDMO Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Gene Cell Therapy CDMO Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Gene Cell Therapy CDMO Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Gene Cell Therapy CDMO Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Gene Cell Therapy CDMO Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Gene Cell Therapy CDMO Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Gene Cell Therapy CDMO Market Size by Region
    • 8.3.1 Asia-Pacific Gene Cell Therapy CDMO Consumption Value by Region (2021-2032)
    • 8.3.2 China Gene Cell Therapy CDMO Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Gene Cell Therapy CDMO Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Gene Cell Therapy CDMO Market Size and Forecast (2021-2032)
    • 8.3.5 India Gene Cell Therapy CDMO Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Gene Cell Therapy CDMO Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Gene Cell Therapy CDMO Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Gene Cell Therapy CDMO Consumption Value by Type (2021-2032)
  • 9.2 South America Gene Cell Therapy CDMO Consumption Value by Application (2021-2032)
  • 9.3 South America Gene Cell Therapy CDMO Market Size by Country
    • 9.3.1 South America Gene Cell Therapy CDMO Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Gene Cell Therapy CDMO Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Gene Cell Therapy CDMO Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Gene Cell Therapy CDMO Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Gene Cell Therapy CDMO Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Gene Cell Therapy CDMO Market Size by Country
    • 10.3.1 Middle East & Africa Gene Cell Therapy CDMO Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Gene Cell Therapy CDMO Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Gene Cell Therapy CDMO Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Gene Cell Therapy CDMO Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Gene Cell Therapy CDMO Market Drivers
  • 11.2 Gene Cell Therapy CDMO Market Restraints
  • 11.3 Gene Cell Therapy CDMO Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Gene Cell Therapy CDMO Industry Chain
  • 12.2 Gene Cell Therapy CDMO Upstream Analysis
  • 12.3 Gene Cell Therapy CDMO Midstream Analysis
  • 12.4 Gene Cell Therapy CDMO Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Gene Cell Therapy CDMO market size was valued at US$ 2572 million in 2025 and is forecast to a readjusted size of US$ 4279 million by 2032 with a CAGR of 7.6% during review period.
    Gene Cell Therapy CDMO provides end-to-end customized R&D and manufacturing services for advanced therapies such as gene therapy and cell therapy, from process development to production scale-up. Their core strength lies in addressing the extreme complexity of using live cells or viral vectors as "drugs," encompassing vector design and construction, cell collection and modification, process development and optimization, rigorous quality control and release testing, and clinical- and commercial-grade aseptic manufacturing. This field has extremely high barriers to entry, requiring companies to possess cutting-edge biological technologies, GMP-compliant closed-loop automated production systems, and the expertise to meet stringent global regulations. They are indispensable industrialization partners for pharmaceutical companies to bring cutting-edge therapies from the laboratory to market.
    Gene Cell Therapy CDMO has a highly complex cost structure, primarily including cutting-edge R&D and highly skilled human resources costs, customized GMP facilities and expensive one-time production consumables, as well as stringent quality control and testing fees. Their gross profit margins range widely (typically 30%-60% or higher), depending mainly on the uniqueness of the technology platform, process efficiency, and capacity utilization. Early highly personalized therapies face significant cost pressures due to limited scale, while mature, large-scale platform-based manufacturing (such as allogeneic therapies and viral vectors) can achieve higher profitability through standardization and capacity expansion.
    The global landscape of Gene Cell Therapy CDMO is characterized by "technology leadership, regional concentration, and multi-point breakthroughs." North America remains the absolute innovation center and largest source of demand globally, boasting the most mature capital markets, top biotech companies, and leading CDMO firms, dominating technology and standard development. Europe follows closely behind, possessing strong capabilities in specific technological routes and clinical translation thanks to its deep research foundation and rigorous regulatory system. The Asia-Pacific region, especially China, is becoming the fastest-growing market globally, driven by strong policy support, the rise of domestic innovative pharmaceutical companies, and huge clinical demand. It is rapidly moving from early technology imports to independent innovation and internationalization, with South Korea and Japan also actively expanding their presence. Currently, supply chain stability, geopolitical factors, and the need for proximity to clinical centers are driving the global production capacity layout towards regionalization and diversification.
    This report is a detailed and comprehensive analysis for global Gene Cell Therapy CDMO market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Gene Cell Therapy CDMO market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Gene Cell Therapy CDMO market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Gene Cell Therapy CDMO market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Gene Cell Therapy CDMO market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Gene Cell Therapy CDMO
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Gene Cell Therapy CDMO market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Catalent, Lonza, Charles River, Oxford Biomedica, Novartis, OBiO, GenScript, Pharmaron, Porton, Resilience, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Gene Cell Therapy CDMO market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Immune Cells
    Stem Cell
    Viral Vector
    Plasmid DNA
    Market segment by Stage
    Early-stage CDMO and preclinical CDMO
    Clinical-stage CDMO
    Commercial-stage CDMO
    Market segment by Production Mode
    Centralized Factory Model
    Distributed Regional Production Model
    Market segment by Application
    Pharmaceutical and Biotechnology Companies
    Research and Academic Institutions
    Hospital
    Others
    Market segment by players, this report covers
    Catalent
    Lonza
    Charles River
    Oxford Biomedica
    Novartis
    OBiO
    GenScript
    Pharmaron
    Porton
    Resilience
    SK Pharmteco
    Forge Biologics
    Andelyn Biosciences
    Roslin CT
    eXmoor Pharma
    Advanced Therapies
    Catalent Biologics
    Patheon Pharma Services
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Gene Cell Therapy CDMO product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Gene Cell Therapy CDMO, with revenue, gross margin, and global market share of Gene Cell Therapy CDMO from 2021 to 2026.
    Chapter 3, the Gene Cell Therapy CDMO competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Gene Cell Therapy CDMO market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Gene Cell Therapy CDMO.
    Chapter 13, to describe Gene Cell Therapy CDMO research findings and conclusion.

    Buy now